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In this issue of the Journal of Headache and Pain, Yurekli
et al. show that sodium valproate (VPA) is effective in the
preventive treatment of chronic daily headache (CDH) over
placebo [1]. Even though the number of treated patients in
their trial is not high, this study is relevant as it is the first
double-blind, randomized, placebo-controlled trial with
VPA. In their experience, there was a trend for a better
efficacy in chronic migraine patients.
This study confirms both the previous results, obtained
with open designs, with this drug [2, 3] and the recent
data coming from randomized, double-blind, placebo-
controlled clinical trials using topiramate as the active
drug [4–6]. An important conclusion of these trials is that
topiramate was seen to be effective in chronic migraine
patients who still met overuse criteria, which denies the
idea that these patients are refractory to preventatives.
Yurekli and his group do not specify whether their
patients met the overuse criteria or not, but as abuse was
not an exclusion reason in this trial, we can assume that at
least around two-thirds were overusers as they were
actively seeking consultations.
CDH, especially chronic migraine, is one of the most
disabling headaches and a frequent reason for consultation
in neurology departments, accounting for at least one-
third of the visits to headache centers. How should these
patients be managed from a practical point of view? In
our opinion, the management of these patients should not
be based only on analgesic withdrawal. Rational use of
acute treatment, of course, continues to be a milestone in
their management, trying to limit its use to \2–3 days/
week and avoiding abortive medications with high evi-
dence of rebound, such as combination analgesics,
opioids, and ergotics. In clinical practice, withdrawal
alone is not enough for most patients and we would
recommend starting preventatives from the beginning.
There are now conclusive data showing that VPA and
topiramate as well as amitriptyline are efficacious in CDH
patients. No controlled results are available for other oral
drugs, for instance b-blockers, but they could also be
considered for this indication in clinical practice. For
patients with no response to these medications, we have
shown that combination therapy (a b-blocker + either
VPA or topiramate) at rather low doses can be effective,
possibly as they have synergistic, complementary mech-
anisms of action [7, 8]. Not only an early use of
preventatives is important, but also a prolonged admin-
istration is usually necessary: around 50% of responders
need preventatives for periods longer than 1 year [9].
Patients with insufficient response to symptomatic
medication withdrawal and oral preventatives are not rare
and are very difficult to treat. Adding botulinum toxin type
A injections can help these patients, as has been found in
many open studies and as shown in preliminary phase II
trials [10]. Finally, while waiting for more potent and
specific preventatives, desperate chronic migraine patients
can still be offered treatment with suboccipital stimulators,
which preliminarily, have been shown to reduce the pain
frequency and intensity in around three-quarters of chronic
migraine patients [11].
As one of us wrote in an Editorial in this Journal 2 years
ago [12], we should change the way we treat CDH patients.
Their management is not obviously easy, but reverting a
chronic migraine patient to an episodic one is highly
rewarding.
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